Emily Bodnar
Stock Analyst at H.C. Wainwright
(4.02)
# 1,714
Out of 4,463 analysts
640
Total ratings
37.3%
Success rate
6.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COAG Hemab Therapeutics Holdings | Maintained: Buy | $40 | $32.50 | +23.08% | 2 | Jun 26, 2026 | |
| NVCR NovoCure | Maintained: Buy | $46 | $15.78 | +191.51% | 43 | Jun 22, 2026 | |
| AGIO Agios Pharmaceuticals | Reiterated: Buy | $50 → $54 | $37.08 | +45.63% | 20 | Jun 15, 2026 | |
| ATOS Atossa Therapeutics | Rated: Hold | n/a | $2.04 | - | 27 | Jun 15, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $10 | $3.88 | +157.73% | 11 | Jun 15, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $5 | $0.6083 | +721.96% | 38 | Jun 15, 2026 | |
| TGTX TG Therapeutics | Maintained: Buy | $70 | $53.52 | +30.79% | 10 | Jun 9, 2026 | |
| ARTV Artiva Biotherapeutics | Maintained: Buy | $35 | $9.80 | +257.14% | 9 | Jun 8, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $32 | $28.92 | +10.65% | 18 | Jun 3, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $38 | $12.08 | +214.57% | 46 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $34.73 | +29.57% | 10 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $3.41 | +574.49% | 38 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $1.75 | +1,614.29% | 19 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.06 | +1,032.08% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $11.46 | +205.41% | 26 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $18.62 | +61.12% | 2 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $1.73 | +998.27% | 23 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 → $10 | $1.58 | +532.91% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $2.85 | +461.40% | 30 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.56 | +96.63% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31 | $2.90 | +968.97% | 15 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.27 | - | 13 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.88 | +1,229.79% | 26 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 → $66 | $65.43 | +0.87% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $0.4545 | +4,300.44% | 21 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $6.05 | +197.52% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $1.95 | +925.64% | 14 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.0061 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56.88 | $4.64 | +1,125.76% | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $4.35 | +3,578.16% | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.65 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.39 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.02 | n/a | 6 | May 22, 2024 |
Hemab Therapeutics Holdings
Jun 26, 2026
Maintained: Buy
Price Target: $40
Current: $32.50
Upside: +23.08%
NovoCure
Jun 22, 2026
Maintained: Buy
Price Target: $46
Current: $15.78
Upside: +191.51%
Agios Pharmaceuticals
Jun 15, 2026
Reiterated: Buy
Price Target: $50 → $54
Current: $37.08
Upside: +45.63%
Atossa Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.04
Upside: -
SAB Biotherapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $10
Current: $3.88
Upside: +157.73%
Context Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $5
Current: $0.6083
Upside: +721.96%
TG Therapeutics
Jun 9, 2026
Maintained: Buy
Price Target: $70
Current: $53.52
Upside: +30.79%
Artiva Biotherapeutics
Jun 8, 2026
Maintained: Buy
Price Target: $35
Current: $9.80
Upside: +257.14%
Arcus Biosciences
Jun 3, 2026
Maintained: Buy
Price Target: $32
Current: $28.92
Upside: +10.65%
Olema Pharmaceuticals
Jun 3, 2026
Reiterated: Buy
Price Target: $38
Current: $12.08
Upside: +214.57%
May 26, 2026
Maintained: Buy
Price Target: $45
Current: $34.73
Upside: +29.57%
May 22, 2026
Maintained: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
May 18, 2026
Reiterated: Buy
Price Target: $30
Current: $1.75
Upside: +1,614.29%
May 15, 2026
Maintained: Buy
Price Target: $12
Current: $1.06
Upside: +1,032.08%
May 15, 2026
Maintained: Buy
Price Target: $35
Current: $11.46
Upside: +205.41%
May 15, 2026
Reiterated: Buy
Price Target: $30
Current: $18.62
Upside: +61.12%
May 14, 2026
Reiterated: Buy
Price Target: $19
Current: $1.73
Upside: +998.27%
May 13, 2026
Rated: Buy
Price Target: $9 → $10
Current: $1.58
Upside: +532.91%
May 13, 2026
Maintained: Buy
Price Target: $16
Current: $2.85
Upside: +461.40%
May 12, 2026
Reiterated: Buy
Price Target: $7
Current: $3.56
Upside: +96.63%
May 8, 2026
Maintained: Buy
Price Target: $31
Current: $2.90
Upside: +968.97%
May 6, 2026
Maintained: Hold
Price Target: n/a
Current: $1.27
Upside: -
Apr 2, 2026
Maintained: Buy
Price Target: $25
Current: $1.88
Upside: +1,229.79%
Mar 30, 2026
Maintained: Buy
Price Target: $55 → $66
Current: $65.43
Upside: +0.87%
Mar 30, 2026
Rated: Buy
Price Target: $20
Current: $0.4545
Upside: +4,300.44%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $6.05
Upside: +197.52%
Nov 17, 2025
Reiterated: Buy
Price Target: $20
Current: $1.95
Upside: +925.64%
Nov 17, 2025
Maintained: Hold
Price Target: n/a
Current: $0.0061
Upside: -
Oct 13, 2025
Maintained: Buy
Price Target: $56.88
Current: $4.64
Upside: +1,125.76%
Sep 26, 2025
Maintained: Buy
Price Target: $160
Current: $4.35
Upside: +3,578.16%
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $7.65
Upside: n/a
Mar 31, 2025
Maintained: Buy
Price Target: $8
Current: $2.39
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $4.02
Upside: n/a